With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.82019-32-7,7-Bromo-1-methyl-1H-quinoxalin-2-one,as a common compound, the synthetic route is as follows.
82019-32-7, Add the substrate 1-methyl-7-bromoquinoxaline-2(1H)-one to a 15 ml reaction tube 71.7 mg, 0.3 mmol, the substituent on the structural formula R1 is a methyl group, and R2 is a bromine atom), Sodium trifluoromethylsulfinate (CF3SO2Na, 140.5 mg, 0.9 mmol), An oxidizing agent iodobenzene bis(trifluoroacetate) (387.0 mg, 0.9 mmol) was added. The oil pump was evacuated, filled with argon gas, and repeated 3 times, and 3 ml of acetonitrile was added by a syringe. The mixture was stirred at room temperature under an argon atmosphere for 12 hours. The reaction was confirmed to be completely complete by TLC. The solvent acetonitrile was distilled off and then directly purified by column chromatography (ethyl acetate / petroleum ether = 1/3) to give the produc 1-methyl-3-trifluoromethyl-7-bromoquinoxaline-2(1H)-one 49.8 mg, total yield 54%.
As the paragraph descriping shows that 82019-32-7 is playing an increasingly important role.
Reference£º
Patent; Hebei University of Technology; Zhang Hongyu; Wang Liping; Zhang Yuecheng; Zhao Jiquan; (13 pag.)CN108976174; (2018); A;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider